Background
==========

It is unclear what constitutes a clinically-meaningful response for allergic rhinitis (AR) outcomes. In a recent survey \[[@B1]\] most experts defined control as being \"hardly troubled at all\" by each symptom. We propose a new criterion of ≤1 point remaining in each nasal symptom score (Max AM+PM score for each symptom=6) of the reflective total nasal symptom score (rTNSS) to stringently test efficacy and provide an endpoint meaningful to physicians and patients. This criterion has been termed complete/near-to-complete symptom control. Any treatment providing this level of control (patients will feel \"cured\") should have considerable socioeconomic impact.

Objective
=========

To compare the proportion of patients achieving ≤1 point remaining in each of the 4 symptoms of the rTNSS (congestion, itching, rhinorrhoea & sneezing) and the time taken to achieve this response in patients treated with MP29-02\* (a novel intranasal formulation of azelastine hydrochloride \[AZE\] and fluticasone propionate \[FP\]), FP, AZE or placebo (PLA) nasal sprays.

Methods
=======

610 patients (≥12 years old) with moderate-to-severe seasonal AR were randomized into a double-blind, placebo-controlled, 14 day parallel-group trial to receive MP29-02\*, commercially-available AZE or FP nasal sprays or PLA nasal spray (all 1 spray/nostril bid; total daily dose \[AZE: 548µg, FP: 200µg\]). The primary outcome was change from baseline in rTNSS over 14-days. Time to achieve ≤1 point remaining in each nasal symptom (AM + PM) of the rTNSS was assessed post-hoc by Kaplan-Meier estimates and log rank tests.

Results
=======

17.8% of MP29-02\* patients (1 out of 6) achieved this response versus 8.3%, 9.2% and 7.8% of those treated with AZE, FP and PLA, respectively. MP29-02\* patients achieved this response up to 7 days faster than AZE (p=0.0152) and up to 8 days faster than either FP (p=0.0262) or PLA (p=0.0094). Neither AZE nor FP differed from PLA for this parameter.

Conclusion
==========

MP29-02\* provides faster and more complete symptom control than first-line therapies for AR. One out of 6 moderate to severe AR patients achieved complete/near-to-complete and uniform symptom relief days faster than either FP or AZE. MP29-02\* is the drug of choice for AR treatment since it was the only therapy to rapidly provide such a level of symptom control. This endpoint should become a new standard in assessing the efficacy of current and novel AR therapy.
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